A randomized trial of cognitive-behavioral therapy or selective serotonin reuptake inhibitor or both combined for panic disorder with or without agoraphobia: Treatment results through 1-year follow-up

Journal of Clinical Psychiatry

Volumn 71, Issue 5, 2010, Pages 574-586

  Van Apeldoorn, Franske J ^a   Timmerman, Marieke E ^b   Mersch, Peter Paul A ^a   Van Hout, Wiljo J P J ^b   Visser, Sako ^c   Van Dyck, Richard ^c   Den Boer, Johan A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SERTRALINE;

ADULT; AGORAPHOBIA; ANXIETY; ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COPING BEHAVIOR; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; NAUSEA; NERVOUSNESS; NETHERLANDS; OUTCOME ASSESSMENT; PANIC; PATIENT SATISFACTION; PREDICTOR VARIABLE; PRETEST POSTTEST DESIGN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STRUCTURED INTERVIEW; SWEATING; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; WEAKNESS;

ADULT; AGORAPHOBIA; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; PANIC DISORDER; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952614691     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04681blu     Document Type: Article

References (43)

1. Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am J Psychiatry. 2000;157(5):669-682. (Pubitemid 30249642)
2. DuPont RL, Rice DP, Miller LS, et al. Economic costs of anxiety disorders. Anxiety. 1996;2(4):167-172.
3. Salvador-Carulla L, Seguí J, Fernández-Cano P, et al. Costs and offset effect in panic disorders. Br J Psychiatry Suppl. 1995;(27):23-28.
4. Keller MB, Yonkers KA, Warshaw MG, et al. Remission and relapse in subjects with panic disorder and panic with agoraphobia: a prospective short-interval naturalistic follow-up. J Nerv Ment Dis. 1994;182(5):290-296.
5. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on panic disorder from the international consensus group on depression and anxiety. J Clin Psychiatry. 1998;59(suppl 8):47-54. (Pubitemid 28354619)
6. den Boer JA, Slaap BR, ter Horst GJ, et al. Therapeutic armamentarium in anxiety disorders. In: D'Haenen H, Den Boer JA, Willner P, eds. Biological Psychiatry. London, United Kingdom: John Wiley & Sons; 2002:1039-1062.
7. Otto MW, Deveney C. Cognitive-behavioral therapy and the treatment of panic disorder: efficacy and strategies. J Clin Psychiatry. 2005;66(suppl 4):28-32. (Pubitemid 40637723)
8. Rayburn NR, Otto MW. Cognitive-behavioral therapy for panic disorder: a review of treatment elements, strategies, and outcomes. CNS Spectr. 2003;8(5):356-362. (Pubitemid 36765018)
9. Furukawa TA, Watanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br J Psychiatry. 2006;188(4):305-312.
10. Barlow DH, Gorman JM, Shear MK, et al. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA. 2000;283(19):2529-2536.
11. Otto MW, Smits JAJ, Reese HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clin Psychol Sci Pract. 2005;12(1):72-86.
12. Bouton ME. Context and ambiguity in the extinction of emotional learning: implications for exposure therapy. Behav Res Ther. 1988;26(2):137-149.
13. Vansteenwegen D, Hermans D, Vervliet B, et al. Return of fear in a human differential conditioning paradigm caused by a return to the original acquistion [sic] context. Behav Res Ther. 2005;43(3):323-336. (Pubitemid 40169981)
14. Bouton ME. A learning theory perspective on lapse, relapse, and the maintenance of behavior change. Health Psychol. 2000;19(suppl):57-63.
15. Hermans D, Craske MG, Mineka S, et al. Extinction in human fear conditioning. Biol Psychiatry. 2006;60(4):361-368.
16. Craske MG. An integrated treatment approach to panic disorder. Bull Menninger Clin. 1996;60(2 suppl A):A87-A104.
17. van Apeldoorn FJ, van Hout WJPJ, Mersch PPA, et al. Is a combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia. Acta Psychiatr Scand. 2008;117(4):260-270.
18. Slaap BR, den Boer JA. The prediction of nonresponse to pharmacotherapy in panic disorder: a review. Depress Anxiety. 2001;14(2):112-122. (Pubitemid 32937485)
19. Steketee G, Shapiro LJ. Predicting behavioral treatment outcome for agoraphobia and obsessive compulsive disorder. Clin Psychol Rev. 1995;15(4):317-346.
20. Clark DM. A cognitive approach to panic. Behav Res Ther. 1986;24(4):461-470.
21. Craske MG, Barlow DH. Panic disorder and agoraphobia. In: Barlow DH, ed. Clinical Handbook of Psychological Disorders. New York, NY: Guilford; 1993:1-47.
22. van Balkom AJLM, van Dyck R, van Megen HJGM, et al. Richtlijn Farmacotherapie Angststoornissen. Amsterdam, The Netherlands: Dries van Ingen, Uitgeverij Boom; 1998:7-37.
23. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
24. Telch MJ, Brouillard M, Telch CF, et al. Role of cognitive appraisal in panic-related avoidance. Behav Res Ther. 1989;27(4):373-383. (Pubitemid 19206446)
25. Feske U, de Beurs E. The Panic Appraisal Inventory: psychometric properties. Behav Res Ther. 1997;35(9):875-882. (Pubitemid 27390087)
26. Roy-Byrne PP, Craske MG, Stein MB, et al. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Arch Gen Psychiatry. 2005;62(3):290-298.
27. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59(1):12-19.
28. Marks IM, Mathews AM. Brief standard self-rating for phobic patients. Behav Res Ther. 1979;17(3):263-267.
29. Hays RD. RAND-36 Health Status Inventory. San Antonio, TX: The Psychological Corporation; 1998.
30. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.
31. Attkisson CC, Zwick R. The client satisfaction questionnaire. Psychometric properties and correlations with service utilization and psychotherapy outcome. Eval Program Plann. 1982;5(3):233-237.
32. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57.
33. Schotte CKW, de Doncker D, Vankerckhoven C, et al. Self-report assessment of the DSM-IV personality disorders. Measurement of trait and distress characteristics: the ADP-IV. Psychol Med. 1998;28(5):1179-1188. (Pubitemid 28458474)
34. Snijders TAB, Bosker RJ. Multilevel Analysis. London, United Kingdom: Sage; 2000.
35. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York, NY: Springer; 2000.
36. Rasbash J, Woodhouse G. MLn Command Reference. London, United Kingdom: Institute of Education, University of London; 1995.
37. Agresti A, Caffo B. Simple and effective confidence intervals for proportions and differences of proportions result from adding two successes and two failures. Am Stat. 2000;54(4):280-288. (Pubitemid 33204723)
38. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;22(158):209-212.
39. De Brey H. A cross-national validation of the Client Satisfaction Questionnaire: the Dutch experience. Eval Program Plann. 1983;6(3-4):395-400.
40. Miklowitz DJ. Psychological treatment and medication for the mood and anxiety disorders: moderators, mediators, and domains of outcome. Clin Psychol Sci Pract. 2005;12(1):97-99.
41. Bouchard S, Gauthier J, Nouwen A, et al. Temporal relationship between dysfunctional beliefs, self-efficacy and panic apprehension in the treatment of panic disorder with agoraphobia. J Behav Ther Exp Psychiatry. 2007;38(3):275-292. (Pubitemid 47069231)
42. Sharp DM, Power KG, Simpson RJ, et al. Fluvoxamine, placebo, and cognitive behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia. J Anxiety Disord. 1996;10(4):219-242.
43. Başoĝlu M, Marks IM, Kiliç C, et al. Alprazolam and exposure for panic disorder with agoraphobia. Attribution of improvement to medication predicts subsequent relapse. Br J Psychiatry. 1994;164(5):652-659. (Pubitemid 24161264)